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Editorial
Group for Research and Assesment of Psoriasis and 
Psoriatic Arthritis-GRAPPA (2003-2013)
The common concept of rheumatologists and dermatologists 
to deal with the combined evaluation of patients with psoria-
sis (PsO) and psoriatic arthritis (PsA) have led to the founda-
tions of Group for Research and Assessment of Psoriasis and 
Psoriatic Arthritis (GRAPPA), now in its 10th anniversary. This 
editorial looks over the past ten years until the last meeting 
in Toronto last July.
A history of success
The association of PsO with articular manifestations, simi-
larly to what was also known with infl ammatory bowel dis-
ease and uveitis, have been known for long time, although the 
mechanism behind these clinical observations were and still 
are only partially understood. It was only in 1973 that John 
Moll and Verna Wright have tried to create fundamentals that 
would identify in a patient with psoriasis that he was also 
suffering from PsA (Table 1).1
Using these diagnostic criteria, Moll and Wright described 
fi ve subgroups of PsA: distal interphalangeal (DIP), asym-
metrical oligoarthritis, polyarthritis, spondylitis, and arthritis 
mutilans.
In the 90’s several other classifi cations were proposed by 
different authors and were reviewed by Gladman and Espi-
noza.2 In the past decade an international group assembled 
what is now known as the Classifi cation of Psoriatic Arthritis 
criteria (CASPAT).The original diagnostic criteria of Moll and 
Wright are now being replaced by the CASPAR criteria.3 CAS-
PAR takes into account the presence of articular manifesta-
tions, the presence of skin disease or familial history, typical 
nail changes, the presence of swelling of the digit and juxtar-
ticular bone in formation. It was shown that CASPAR has a 
sensibility of 98.7% and a specifi city of 91.4%.
GRAPPA is a non-profi t educational and scientifi c organi-
zation, created to facilitate sharing of information that relates 
to PsO and PsA. It was initiated 10 years ago with their fi rst 
meeting in New York City (Fig. 1). Its objectives include: 1) Pro-
mote the development of national and international collab-
orative registries of PsA and PsO patients to standardize the 
data being obtained and learn more about the natural history 
of the disease as well as its genetic underpinnings; 2) Work 
closely with representatives of patient service leagues to pro-
mote public education and awareness of PsA and PsO; 3) Work 
closely with representatives of biopharmaceutical companies to 
promote and conduct research on effective therapies for PsA 
and PsO; 4) Work closely with representatives of regulatory 
agencies to establish appropriate guidelines for regulatory 
approval of new therapies; 5) Work with other professional 
Table 1 – Moll and Wright criteria for identifi cation of 
psoriatic arthritis.
Infl ammatory arthritis (peripheral arthritis and/or sacoiliitis and 
spondylitis)
The presence of psoriasis
The usual absence of serological tests for rheumatoid factor
Fig 1 – First GRAPPA meeting, New York, 2003. From left 
to right Mease, Zimmerman, Gladman, third row Khan, 
Helliwell, Nash, Ritchlin, Landwee, Espinoza, Smolen, 
Fitzgerald, Braun, Kalden, Antoni van der Bosch and 
Kavanaugh..
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bodies, such as the American College of Rheumatology, Amer-
ican Academy of Dermatology, and OMERACT to promote 
knowledge of research about PsA and PsO within the context 
of those disciplines; and 6) Develop treatment guidelines for 
governmental and other interested parties.
Important publications that are now standard references were 
published during the past fi ve years and are listed in Table 2:
Brazil have been an active participant in the mission of 
GRAPPA in Latin America with national meetings throughout 
in Brazil and Latin America; several Brazilian rheumatologists 
and dermatologists are now working together for the benefi t 
of patients with both diseases.The fi rst joined meeting was 
held in Porto Alegre (RS, Brazil) together with the Brazilian 
Congress; the second meeting was held in Fortaleza (CE, Bra-
zil) in 2012 and the third will be in Salvador (BA, Brazil), on 
the second semester of this year.4 Last July, together with the 
35th anniversary of the creation of the Psoriatic Arthritis Clinic 
at the University of Toronto, GRAPPA was commemorating its 
10th anniversary since its inception in New York. The Brazil-
ian rheumatologists Claudia Schainberg, Roberto Ranza, Sueli 
Carneiro, Penelope Pelarminos, Rachel Gryzpan and myself 
attended the event (Fig. 2).
As of today Brazil has 29 members affi liated with GRAPPA 
15 of them are rheumatologists.New projects are being de-
signed with participation of Brazilian rheumatologists in the 
upcoming years. The projects are listed below.
 
• New projects are being developed in refi nement and vali-
dation of arthritis outcome measures in PsA
• Development of instruments to assess QOL, function, and 
participation
• Standardization of histologic and immunohistochemical 
assessments in PsA and PsO
• Updated criteria for classifi cation of PsA (CASPAR)
• Imaging in PsA.
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